Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TRAF3-interacting protein 1 (TRAF3IP1) is a cytoplasmic protein that interacts with TNF receptor-associated factor 3 (TRAF3) and tethers it to cytoskeletal microtubules. TRAF3IP1 also acts as an inhibitor of the innate type I interferon (IFN) response and suppresses interleukin-13 (IL-13) signaling by binding to the interleukin-13 receptor alpha 1 (IL13RA1). It recruits TRAF3 and DISC1 to microtubules, playing a key role in epithelial morphogenesis, kidney development, ciliogenesis, and the regulation of microtubule cytoskeleton organization and stability via MAP4. Mutations in this gene are linked to Senior-Loken syndrome 9 and specific ciliopathies, highlighting its importance in cellular architecture and signaling[1][3][6][7][8]. Notes: - TRAF3IP1 is not currently considered a primary therapeutic target such as a receptor, enzyme, transporter, or typical drug target[1][3][8]. - No drugs, biomarkers, or established safety concerns are associated with this protein in standard reference sources as of the current knowledge base[1][3][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TRAF3-interacting protein 1 (TRAF3IP1).